Pressure on aducanumab price from lawmakers grows as House begins investigation

Joining calls from the Senate to act on Biogen’s aducanumab, House committees on Oversight and Reform and Energy and Commerce announced Friday that they have launched an investigation into the approval and pricing of the newly approved Alzheimer’s therapy.

Rep. Carolyn Maloney (D-N.Y.), chairwoman of the Oversight and Reform Committee, and Rep. Frank Pallone, Jr. (D-N.J.), chairman of the Committee on Energy and Commerce, said they “have serious concerns about the steep price” of Aduhelm aducanumab from  Biogen Inc. (NASDAQ:BIIB) “and the process that led to its approval despite questions about the drug’s clinical benefit.” ...